Market Intelligence, Clinical Progress, and High-Purity Reagents for Ovarian & Solid Tumor ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FOLR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FOLR1 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View FOLR1 Products |
| Gene Delivery | FOLR1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Suitable for flow cytometry and internalization assays. | View FOLR1 Products |
| Benchmark Ab | Anti-FOLR1 (Sequence of Mirvetuximab). Recombinant positive control for assay development and biosimilar benchmarking. | View FOLR1 Products |
| Validator | FOLR1 siRNA Set. For knockdown verification and assay specificity controls. | View FOLR1 Products |
| Related Target A (FOLR2) | FOLR2 (FRβ). Closest paralog for subfamily off-target and selectivity counter-screening. | View FOLR2 Products |
| Related Target B (MSLN) | MSLN. Synergistic target often co-expressed in ovarian carcinomas. | View MSLN Products |
| Related Target C (TROP2) | TACSTD2 (TROP2). Complementary solid-tumor ADC target for combination therapy screening. | View TACSTD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Epitopes | HEK293 Expressed (Native Glycosylation), preserving correct ECD folding. |
| Subfamily Counter Screening (FOLR2/FOLR3) | Homolog panel proteins available, strictly sequence verified and high purity (>95%). |
| Lack of Controls for ADC Internalization | Clinical Benchmark Antibodies (Biosimilars) included for comparative assay scaling. |
| False Positives in Flow Cytometry | Validated siRNA included for precise specificity checks and background determination. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. Sequence Verified. |
| ADC Internalization & Trafficking | Full-length Lentivirus for stable cell line construction. Preserves native conformation for flow cytometry. |
Live FOLR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FOLR1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic and validate the target in platinum-resistant ovarian cancer, the next wave of R&D is targeting lower-expressing tumors, combination therapies, and novel payloads. Bystander effect optimization and bispecific formats are heavily prioritized in current preclinical paradigms. Following the clinical validation, the pipeline is rapidly expanding into non-small cell lung cancer and endometrial carcinomas, with combination regimens involving PARP inhibitors and immunotherapy under active investigation. Resistance mechanisms such as antigen shedding and alternative folate transport upregulation are being addressed through innovative assay strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | ImmunoGen/AbbVie, Sutro/Merck, Eisai | Ovarian, Endometrial, NSCLC | Internalization Assay (Need high-purity HEK293 expressed ECD-Fc and stable cell lines) |
| Bispecific/TCE | Regeneron, Genmab, Emerging Biotechs | Solid Tumors (Immunotherapy) | Selectivity Assay (Need FOLR2 counter-screening proteins) |
| CAR-T | Bristol Myers Squibb, Various BioTechs | Refractory Ovarian Cancer | On-Target/Off-Tumor Toxicity Checks (Need FOLR2/3 counter-screen proteins) |
| Small Molecule (SMDC) | Endocyte (Novartis) | Solid Tumors | Selectivity Assay (Strictly Endotoxin Controlled <1EU/µg proteins) |
| Radioligand Conjugates | Industry R&D Pipelines | Ovarian / Endometrial Cancer | Cell Line Construction (Need full-length Lentivirus) |
Key Genetic Variants
FOLR1 gene contains notable single nucleotide polymorphisms that may influence protein function or disease susceptibility. Documented variants include rs7928649 (UniProt VAR_059284) and rs1801932 (UniProt VAR_011963). Understanding these polymorphisms is critical for patient stratification and resistance profiling in clinical development.